Treatment of newly diagnosed glioblastoma multiforme.
Carsten
C
Nieder
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D017322:Clinical Trials, Phase II as Topic; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D015201:Meta-Analysis as Topic; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D000077204:Temozolomide; D019063:Tenascin / Q000276:immunology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018906:Antineoplastic Agents, Alkylating; D019063:Tenascin; D003606:Dacarbazine; D000077204:Temozolomide